AU2017378783A1 - Cyclic dinucleotide sting agonists for cancer treatment - Google Patents
Cyclic dinucleotide sting agonists for cancer treatment Download PDFInfo
- Publication number
- AU2017378783A1 AU2017378783A1 AU2017378783A AU2017378783A AU2017378783A1 AU 2017378783 A1 AU2017378783 A1 AU 2017378783A1 AU 2017378783 A AU2017378783 A AU 2017378783A AU 2017378783 A AU2017378783 A AU 2017378783A AU 2017378783 A1 AU2017378783 A1 AU 2017378783A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- group
- alkynyl
- alkenyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C[n]1c(N=CNC2=*)c2nc1 Chemical compound C[n]1c(N=CNC2=*)c2nc1 0.000 description 6
- DMQJHEHHWMWGBH-KGVWEPGKSA-N Nc1ncnc2c1nn[n]2[C@@H](C1(F)F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nn[n]2[C@@H](C1(F)F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O DMQJHEHHWMWGBH-KGVWEPGKSA-N 0.000 description 3
- GKWLKXKXJYLBGO-UHFFFAOYSA-N CC(C)[n]1c(cnnc2N)c2nc1 Chemical compound CC(C)[n]1c(cnnc2N)c2nc1 GKWLKXKXJYLBGO-UHFFFAOYSA-N 0.000 description 2
- QOMIZXMHBKHHPI-UHFFFAOYSA-N CC(C)[n]1c(nnnc2N)c2nc1 Chemical compound CC(C)[n]1c(nnnc2N)c2nc1 QOMIZXMHBKHHPI-UHFFFAOYSA-N 0.000 description 2
- PJIKJWZUUZCBMP-UHFFFAOYSA-N CC(C)[n]1nnc2c1nccc2Cl Chemical compound CC(C)[n]1nnc2c1nccc2Cl PJIKJWZUUZCBMP-UHFFFAOYSA-N 0.000 description 2
- SDSVBSGTPJSAAS-UHFFFAOYSA-N CC(C)[n]1nnc2c1nccc2N Chemical compound CC(C)[n]1nnc2c1nccc2N SDSVBSGTPJSAAS-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1OP3(S)=O YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- BHUCLZKQTSRSAY-UHFFFAOYSA-N C=C1NC(N)=Nc2c1nc[n]2C(C(C1)OP(OCC(C(C2)O3)OC2[n]2c4ncnc(N)c4cc2)(S)=O)OC1CO[P]3=O Chemical compound C=C1NC(N)=Nc2c1nc[n]2C(C(C1)OP(OCC(C(C2)O3)OC2[n]2c4ncnc(N)c4cc2)(S)=O)OC1CO[P]3=O BHUCLZKQTSRSAY-UHFFFAOYSA-N 0.000 description 1
- WRXUDHYWQLDMFG-UHFFFAOYSA-N C=P(O)OC(C(COP(O)(OC(CCC(COC1CO)[n]2c(NC(NC3=O)=O)c3nc2)C1O)=O)OCC(CC1)[n]2c(ncnc3N)c3nc2)C1O Chemical compound C=P(O)OC(C(COP(O)(OC(CCC(COC1CO)[n]2c(NC(NC3=O)=O)c3nc2)C1O)=O)OCC(CC1)[n]2c(ncnc3N)c3nc2)C1O WRXUDHYWQLDMFG-UHFFFAOYSA-N 0.000 description 1
- ZCVPLCZDFTXKSB-UHFFFAOYSA-N C=P(OCC(C(C1OP(O)(OCC2OC3[n]4c(ncnc5N)c5nc4)=O)O)OC1[n]1c(N=C(N)NC4=S)c4nc1)OC2C3O Chemical compound C=P(OCC(C(C1OP(O)(OCC2OC3[n]4c(ncnc5N)c5nc4)=O)O)OC1[n]1c(N=C(N)NC4=S)c4nc1)OC2C3O ZCVPLCZDFTXKSB-UHFFFAOYSA-N 0.000 description 1
- HNZKXAAYIJCELB-UHFFFAOYSA-N CC(C)[n]1c(C=CNC2)c2nc1 Chemical compound CC(C)[n]1c(C=CNC2)c2nc1 HNZKXAAYIJCELB-UHFFFAOYSA-N 0.000 description 1
- GSTFEDXYLJOASP-UHFFFAOYSA-N CC(C)[n]1c(C=NNC2=O)c2nc1 Chemical compound CC(C)[n]1c(C=NNC2=O)c2nc1 GSTFEDXYLJOASP-UHFFFAOYSA-N 0.000 description 1
- FHNZYLCFLUYYAJ-UHFFFAOYSA-N CC(C)[n]1c(F)nc2c1ncnc2N Chemical compound CC(C)[n]1c(F)nc2c1ncnc2N FHNZYLCFLUYYAJ-UHFFFAOYSA-N 0.000 description 1
- MMVXHMIFFAGTTP-UHFFFAOYSA-N CC(C)[n]1c(N=C(N)NC2=O)c2nc1 Chemical compound CC(C)[n]1c(N=C(N)NC2=O)c2nc1 MMVXHMIFFAGTTP-UHFFFAOYSA-N 0.000 description 1
- YDXYXPFTXQYYLA-UHFFFAOYSA-N CC(C)[n]1c(N=NNC2)c2nc1 Chemical compound CC(C)[n]1c(N=NNC2)c2nc1 YDXYXPFTXQYYLA-UHFFFAOYSA-N 0.000 description 1
- LLWXDRCTMRAEHR-UHFFFAOYSA-N CC(C)[n]1c(NC(N)=CC2=O)c2nc1 Chemical compound CC(C)[n]1c(NC(N)=CC2=O)c2nc1 LLWXDRCTMRAEHR-UHFFFAOYSA-N 0.000 description 1
- RZIIMNOJHLWYNA-UHFFFAOYSA-N CC(C)[n]1c(ncnc2Cl)c2nc1 Chemical compound CC(C)[n]1c(ncnc2Cl)c2nc1 RZIIMNOJHLWYNA-UHFFFAOYSA-N 0.000 description 1
- URGLBEHKAGLPSW-UHFFFAOYSA-N CC(C)[n]1c2nc(Cl)nc(N)c2nc1 Chemical compound CC(C)[n]1c2nc(Cl)nc(N)c2nc1 URGLBEHKAGLPSW-UHFFFAOYSA-N 0.000 description 1
- WIJJVFRRTKRLDN-UHFFFAOYSA-N CC(C)[n]1c2nc(F)nc(N)c2nc1 Chemical compound CC(C)[n]1c2nc(F)nc(N)c2nc1 WIJJVFRRTKRLDN-UHFFFAOYSA-N 0.000 description 1
- SNRRUVSDZBYKMB-UHFFFAOYSA-N CC(C)[n]1nnc2c1ncnc2N Chemical compound CC(C)[n]1nnc2c1ncnc2N SNRRUVSDZBYKMB-UHFFFAOYSA-N 0.000 description 1
- DJEGXCSZPXPBJI-UHFFFAOYSA-N CC(C)c(cn[n]12)c1N=C(N)NC2=O Chemical compound CC(C)c(cn[n]12)c1N=C(N)NC2=O DJEGXCSZPXPBJI-UHFFFAOYSA-N 0.000 description 1
- GNAZEKNFVIEROL-UHFFFAOYSA-N CC(C)c1c2ncnc(N)[n]2nc1 Chemical compound CC(C)c1c2ncnc(N)[n]2nc1 GNAZEKNFVIEROL-UHFFFAOYSA-N 0.000 description 1
- HLHOXUPUXBCGJL-UHFFFAOYSA-N CC(C)c1ccc2[n]1ncnc2N Chemical compound CC(C)c1ccc2[n]1ncnc2N HLHOXUPUXBCGJL-UHFFFAOYSA-N 0.000 description 1
- QWCWYKDHDMAMMC-UHFFFAOYSA-N CC(C)c1cnc2[n]1N=CNC2 Chemical compound CC(C)c1cnc2[n]1N=CNC2 QWCWYKDHDMAMMC-UHFFFAOYSA-N 0.000 description 1
- DBJQPZWYNHAIBE-BYXXVGLGSA-N CC(CNC=N)[C@@]([C@@H]([C@@H](COP(O)(O[C@H]1[C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@H](CO2)[C@H]1O)=O)O)OP2(C)=O)(N)O Chemical compound CC(CNC=N)[C@@]([C@@H]([C@@H](COP(O)(O[C@H]1[C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@H](CO2)[C@H]1O)=O)O)OP2(C)=O)(N)O DBJQPZWYNHAIBE-BYXXVGLGSA-N 0.000 description 1
- SFPFRHORTKYSAB-UHFFFAOYSA-N CCOc1nc(N)nc2c1nc[n]2C(C)C Chemical compound CCOc1nc(N)nc2c1nc[n]2C(C)C SFPFRHORTKYSAB-UHFFFAOYSA-N 0.000 description 1
- WNBMDLUFRFGTKF-UHFFFAOYSA-N CP(OC(C(COP(O)(OC1C([n]2c(N=C(N)NC3=O)c3nc2)OC(CO)C1O)=O)OC1[n](cc2F)c3c2c(N)ncn3)C1O)=O Chemical compound CP(OC(C(COP(O)(OC1C([n]2c(N=C(N)NC3=O)c3nc2)OC(CO)C1O)=O)OC1[n](cc2F)c3c2c(N)ncn3)C1O)=O WNBMDLUFRFGTKF-UHFFFAOYSA-N 0.000 description 1
- PGOVVVRQKVHSOH-JIMCYBNRSA-N CP(OCC([C@H]1O)SC[C@]1([n]1nnc2c1N=C(N)NC2=O)OP(OC1)(S)=O)(O[C@@H](C2)[C@@H]1O[C@H]2c1cnc2[n]1ncnc2N)=O Chemical compound CP(OCC([C@H]1O)SC[C@]1([n]1nnc2c1N=C(N)NC2=O)OP(OC1)(S)=O)(O[C@@H](C2)[C@@H]1O[C@H]2c1cnc2[n]1ncnc2N)=O PGOVVVRQKVHSOH-JIMCYBNRSA-N 0.000 description 1
- JHBKZFZUKKUUPM-SNEOCVOESA-N CP(OC[C@H]([C@@H]([C@H]1OP(O)(OC[C@H]2O[C@H]3[n]4c(ncnc5N)c5nc4)=O)F)O[C@H]1[n]1c(N=C(N)NC4=O)c4nc1)(O[C@H]2[C@H]3O)=O Chemical compound CP(OC[C@H]([C@@H]([C@H]1OP(O)(OC[C@H]2O[C@H]3[n]4c(ncnc5N)c5nc4)=O)F)O[C@H]1[n]1c(N=C(N)NC4=O)c4nc1)(O[C@H]2[C@H]3O)=O JHBKZFZUKKUUPM-SNEOCVOESA-N 0.000 description 1
- XPGVHFGYPFQMGD-JYXCDCNCSA-N CP(OC[C@H]([C@H]([C@H]1OP(O)(OC[C@H]2O[C@H]3[n]4c(ncnc5N)c5nc4)=O)O)O[C@H]1[n]1c(C=CNC4=O)c4nc1)(O[C@H]2[C@H]3O)=O Chemical compound CP(OC[C@H]([C@H]([C@H]1OP(O)(OC[C@H]2O[C@H]3[n]4c(ncnc5N)c5nc4)=O)O)O[C@H]1[n]1c(C=CNC4=O)c4nc1)(O[C@H]2[C@H]3O)=O XPGVHFGYPFQMGD-JYXCDCNCSA-N 0.000 description 1
- JONBYGVPWBZMRT-YZLACOAKSA-N C[C@@H]([C@H]1C)[C@@H](COP(O)(O[C@H]2[C@H]([n]3c(C=CNC4=O)c4nc3)O[C@H](COC)[C@H]2O)=O)O[C@H]1[n]1c(ncnc2N)c2nc1 Chemical compound C[C@@H]([C@H]1C)[C@@H](COP(O)(O[C@H]2[C@H]([n]3c(C=CNC4=O)c4nc3)O[C@H](COC)[C@H]2O)=O)O[C@H]1[n]1c(ncnc2N)c2nc1 JONBYGVPWBZMRT-YZLACOAKSA-N 0.000 description 1
- ZVOCBPQFDKWAIP-UHFFFAOYSA-N C[n](cc1F)c2c1c(N)ncn2 Chemical compound C[n](cc1F)c2c1c(N)ncn2 ZVOCBPQFDKWAIP-UHFFFAOYSA-N 0.000 description 1
- PESGUQRDJASXOR-UHFFFAOYSA-N C[n]1c(N=CNC2=O)c2nc1 Chemical compound C[n]1c(N=CNC2=O)c2nc1 PESGUQRDJASXOR-UHFFFAOYSA-N 0.000 description 1
- MXOUBPWTHPIGIM-UHFFFAOYSA-N Cc1c(N)[n](CNC=C)nc1 Chemical compound Cc1c(N)[n](CNC=C)nc1 MXOUBPWTHPIGIM-UHFFFAOYSA-N 0.000 description 1
- FJRNORWUSSOHGG-UHFFFAOYSA-N Cc1cnc2[n]1ncnc2N Chemical compound Cc1cnc2[n]1ncnc2N FJRNORWUSSOHGG-UHFFFAOYSA-N 0.000 description 1
- BEFDHGMTNXHUFP-OFOUMVFDSA-N NC1=NC=NC23N([C@@H](C4)OC(COP(O)(O[C@H]5[C@H]([n]6c(N=C(N)NC7=O)c7nc6)OC(CO6)[C@H]5F)S)[C@H]4OP6(O)=S)C=CC2C13 Chemical compound NC1=NC=NC23N([C@@H](C4)OC(COP(O)(O[C@H]5[C@H]([n]6c(N=C(N)NC7=O)c7nc6)OC(CO6)[C@H]5F)S)[C@H]4OP6(O)=S)C=CC2C13 BEFDHGMTNXHUFP-OFOUMVFDSA-N 0.000 description 1
- GDZGPZQNJBCWOZ-RNPZHLOYSA-N Nc1c2nc[n]([C@@H]([C@@H]3OC4)O[C@]4(COP(O[C@H]4[C@H]([n]5c(N=C(N)NC6=O)c6nc5)S[C@H](CO5)[C@@H]4F)(S)=O)[C@H]3OP5(S)=O)c2ncn1 Chemical compound Nc1c2nc[n]([C@@H]([C@@H]3OC4)O[C@]4(COP(O[C@H]4[C@H]([n]5c(N=C(N)NC6=O)c6nc5)S[C@H](CO5)[C@@H]4F)(S)=O)[C@H]3OP5(S)=O)c2ncn1 GDZGPZQNJBCWOZ-RNPZHLOYSA-N 0.000 description 1
- IFSJZFXDECKHBF-YTWGRVFTSA-N Nc1ccnc2c1nc[n]2[C@@](CO[C@@H]1COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)([C@@H]1OP3(S)=O)F Chemical compound Nc1ccnc2c1nc[n]2[C@@](CO[C@@H]1COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)([C@@H]1OP3(S)=O)F IFSJZFXDECKHBF-YTWGRVFTSA-N 0.000 description 1
- PMVFWGTZQOCLPV-BTTVZHTHSA-N Nc1ncn[n]2c1ncc2[C@@H](C1)O[C@H](COP(O[C@@](CS[C@@H]2CO3)([C@@H]2O)N2NNC4=C2N=C(N)NC4=O)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncn[n]2c1ncc2[C@@H](C1)O[C@H](COP(O[C@@](CS[C@@H]2CO3)([C@@H]2O)N2NNC4=C2N=C(N)NC4=O)(S)=O)[C@H]1OP3(S)=O PMVFWGTZQOCLPV-BTTVZHTHSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Nc1ncnc2c1nc[nH]2 Chemical compound Nc1ncnc2c1nc[nH]2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- VRCHMBRVIQUHAY-UHFFFAOYSA-N Nc1ncnc2c1nc[n]2C(C1F)OC(COP(O)(OC2C([n]3c(N=C(N)NC4=O)c4nc3)OC(CO3)C2F)=O)C1OP3=O Chemical compound Nc1ncnc2c1nc[n]2C(C1F)OC(COP(O)(OC2C([n]3c(N=C(N)NC4=O)c4nc3)OC(CO3)C2F)=O)C1OP3=O VRCHMBRVIQUHAY-UHFFFAOYSA-N 0.000 description 1
- SQJBIIRNUUAXMI-UHFFFAOYSA-N Nc1ncnc2c1nc[n]2C(C1F)OC(COP(OC2C([n]3c(N=C(N)NC4=O)c4nc3)SC(CO3)C2O)(S)=O)C1OP3=O Chemical compound Nc1ncnc2c1nc[n]2C(C1F)OC(COP(OC2C([n]3c(N=C(N)NC4=O)c4nc3)SC(CO3)C2O)(S)=O)C1OP3=O SQJBIIRNUUAXMI-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-OPSRSLIDSA-N Nc1ncnc2c1nc[n]2[C@@H](C1F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H](C1F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1OP3(S)=O YSUIQYOGTINQIN-OPSRSLIDSA-N 0.000 description 1
- GDZGPZQNJBCWOZ-UNKCTKLQSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1OC2)OC2(COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1OC2)OC2(COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O GDZGPZQNJBCWOZ-UNKCTKLQSA-N 0.000 description 1
- YSUIQYOGTINQIN-CLMXYZJCSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](CO[P@](O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1O[P@@]3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](CO[P@](O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1O[P@@]3(S)=O YSUIQYOGTINQIN-CLMXYZJCSA-N 0.000 description 1
- DMQJHEHHWMWGBH-GVGNCSFUSA-N Nc1ncnc2c1nn[n]2[C@@H](C1(F)F)O[C@H](COP(O[C@H]2C([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nn[n]2[C@@H](C1(F)F)O[C@H](COP(O[C@H]2C([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O DMQJHEHHWMWGBH-GVGNCSFUSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436712P | 2016-12-20 | 2016-12-20 | |
| US62/436,712 | 2016-12-20 | ||
| PCT/US2017/066557 WO2018118665A1 (en) | 2016-12-20 | 2017-12-15 | Cyclic dinucleotide sting agonists for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017378783A1 true AU2017378783A1 (en) | 2019-07-04 |
Family
ID=62627882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017378783A Abandoned AU2017378783A1 (en) | 2016-12-20 | 2017-12-15 | Cyclic dinucleotide sting agonists for cancer treatment |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200113924A1 (https=) |
| EP (1) | EP3558324A4 (https=) |
| JP (1) | JP2020503303A (https=) |
| AU (1) | AU2017378783A1 (https=) |
| CA (1) | CA3047113A1 (https=) |
| RU (1) | RU2019122598A (https=) |
| WO (1) | WO2018118665A1 (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| IL264049B2 (en) | 2016-07-06 | 2023-11-01 | Sperovie Biosciences Inc | Compounds, preparations and methods for treating the disease |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| PE20210255A1 (es) | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| US11021511B2 (en) * | 2017-01-27 | 2021-06-01 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
| WO2018156625A1 (en) * | 2017-02-21 | 2018-08-30 | Board Of Regents,The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
| MX2020002303A (es) | 2017-08-30 | 2020-09-10 | Beijing Xuanyi Pharmasciences Co Ltd | Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon. |
| WO2019046511A1 (en) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
| KR102812783B1 (ko) * | 2017-08-31 | 2025-05-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| EP3697801B1 (en) * | 2017-10-16 | 2024-11-20 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| KR20200098511A (ko) | 2017-11-10 | 2020-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Sting 조절제 화합물, 및 제조 및 사용 방법 |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2020014127A1 (en) | 2018-07-10 | 2020-01-16 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| WO2020023361A1 (en) * | 2018-07-23 | 2020-01-30 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Enhancing anti-tumor response in melanoma cells with defective sting signaling |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| EP3848054B1 (en) | 2018-09-06 | 2025-01-29 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates of cyclic dinucleotide derivatives |
| CN110938104B (zh) * | 2018-09-21 | 2024-07-12 | 上海迪诺医药科技有限公司 | 环状二核苷酸类似物、其药物组合物及应用 |
| WO2020092127A1 (en) | 2018-10-29 | 2020-05-07 | Venenum Biodesign, LLC | Novel sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020092617A1 (en) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody conjugates comprising sting agonists |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| WO2020227421A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| WO2021007160A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| CA3147890A1 (en) * | 2019-07-19 | 2021-01-28 | Immunesensor Therapeutics, Inc. | Antibody-sting agonist conjugates and their use in immunotherapy |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| KR20220094221A (ko) * | 2019-09-25 | 2022-07-05 | 코디악 바이오사이언시즈, 인크. | 종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀 |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| AU2020366354A1 (en) * | 2019-10-14 | 2022-03-17 | Immunesensor Therapeutics, Inc. | Methods of treating cancer with a sting agonist |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| MX2022014110A (es) | 2020-05-15 | 2023-01-30 | Immunesensor Therapeutics Inc | Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario. |
| US12559514B2 (en) | 2020-05-22 | 2026-02-24 | Merck Sharp & Dohme Llc | Synthesis of fluorinated nucleotides |
| EP4192474B1 (en) | 2020-08-07 | 2025-09-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| CN116056765A (zh) | 2020-08-07 | 2023-05-02 | 坦伯公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
| US20240199680A1 (en) * | 2021-04-02 | 2024-06-20 | Merck Sharp & Dohme Llc | Synthesis of fluorinated cyclic dinucleotides |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP2024526874A (ja) | 2021-07-23 | 2024-07-19 | イミューンセンサー セラピューティクス、インコーポレイテッド | サイトカインとのｓｔｉｎｇアゴニスト併用療法 |
| WO2023073560A1 (en) | 2021-10-26 | 2023-05-04 | Grant Demartino Industries Llc | Magnetostrictive piezoelectric nanoassembly as cancer chemotherapeutic |
| GB202304385D0 (en) | 2023-03-24 | 2023-05-10 | Prostate Cancer Res | Combinatorial IL-15 therapy |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160080A1 (es) * | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2014189806A1 (en) * | 2013-05-18 | 2014-11-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| JP2016538344A (ja) * | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| EP3546473B1 (en) * | 2014-12-16 | 2025-12-10 | Kayla Therapeutics | Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
| GB201501462D0 (en) * | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| KR102222186B1 (ko) * | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| JP2018534295A (ja) * | 2015-10-28 | 2018-11-22 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法 |
| CN107849084B (zh) * | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| NZ746112A (en) * | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| PE20210255A1 (es) * | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
-
2017
- 2017-12-15 WO PCT/US2017/066557 patent/WO2018118665A1/en not_active Ceased
- 2017-12-15 AU AU2017378783A patent/AU2017378783A1/en not_active Abandoned
- 2017-12-15 RU RU2019122598A patent/RU2019122598A/ru not_active Application Discontinuation
- 2017-12-15 CA CA3047113A patent/CA3047113A1/en not_active Abandoned
- 2017-12-15 JP JP2019533055A patent/JP2020503303A/ja not_active Withdrawn
- 2017-12-15 US US16/472,043 patent/US20200113924A1/en not_active Abandoned
- 2017-12-15 EP EP17884984.0A patent/EP3558324A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019122598A3 (https=) | 2021-04-06 |
| WO2018118665A1 (en) | 2018-06-28 |
| JP2020503303A (ja) | 2020-01-30 |
| EP3558324A1 (en) | 2019-10-30 |
| CA3047113A1 (en) | 2018-06-28 |
| RU2019122598A (ru) | 2021-01-22 |
| US20200113924A1 (en) | 2020-04-16 |
| EP3558324A4 (en) | 2020-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11285131B2 (en) | Benzo[b]thiophene STING agonists for cancer treatment | |
| AU2017378783A1 (en) | Cyclic dinucleotide sting agonists for cancer treatment | |
| US11312772B2 (en) | Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment | |
| US20190328762A1 (en) | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment | |
| EP4735050A1 (en) | Combination therapies for the treatment of cancer | |
| US11052065B2 (en) | Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist | |
| TW202502813A (zh) | 包含偶聯物的藥物組合的治療方法和用途 | |
| RU2771811C2 (ru) | БЕНЗО[b]ТИОФЕНОВЫЕ АГОНИСТЫ STING ДЛЯ ЛЕЧЕНИЯ РАКА | |
| US20230235077A1 (en) | Materials and methods of treating cancer | |
| WO2020033283A1 (en) | Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc | |
| TW202502382A (zh) | 治療組合及其用途和治療方法 | |
| JP2025016420A (ja) | 非小細胞肺癌を治療するための併用療法 | |
| AU2024350521A1 (en) | Use of an immunoconjugate for the treatment of non-small cell lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |